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b-Blockers are among the most commonly used medications in the
treatment of hypertension. However, 45 years after their initial indi-
cation for that treatment, their place in the treatment of hypertensive
patients is under evaluation and their usefulness has been questioned
based on evidence from meta-analyses of clinical trials. The b-blocker
class consists of various agents with diverse pharmacokinetic and
pharmacodynamic properties including lipo- and hydrophilicity, dura-
tion of action, intrinsic sympathomimetic activity, vasodilation, and
metabolism linked to genetic polymorphisms. Because of their various
properties, some b-blockers are indicated for cardiovascular conditions
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ORESUME
Les b-bloqueurs sont parmi les medicaments les plus frequemment
utilises pour le traitement de l’hypertension arterielle. Cependant, 45
ans après leur indication initiale pour ce traitement, leur place dans le
traitement des patients hypertendus est en cours d’evaluation, et leur
utilite a ete remise en question compte tenu des donnees scientiﬁques
provenant des meta-analyses d’essais cliniques. La classe des b-blo-
queurs consiste en des agents varies ayant des proprietes pharma-
cocinetiques et pharmacodynamiques diverses dont la lipophilie et
l’hydrophilie, la duree d’action, l’activite sympathomimetique intrin-
sèque, la vasodilatation et le metabolisme lie aux polymorphismes
genetiques. En raison de leurs diverses proprietes, certains b-blo-b-Blockers are among the most commonly used medications by Khan and McAlister in 2006 supported the Canadian
in the treatment of hypertension. These agents are among the
oldest antihypertensive agents available for prescription and
much better tolerated than the centrally acting agents and
ganglionic blockers that they replaced. They also offer the
special advantage of being indicated in other cardiovascular
diseases. They are indicated for patients with hypertension
and because they are also indicated for other conditions such
as angina, after myocardial infarction (MI), arrhythmias, rate
control of atrial ﬁbrillation, chronic heart failure, and also in
patients with hyperadrenergic states such as thyrotoxicosis and
even migraine and essential tremor, they are very useful in
hypertensive patients with these other comorbidities. After
publication of the meta-analysis by Lindholm in 2005, the
role of b-blockers for the management of hypertension has
come under question,1 and some guidelines groups no longer
recommend them as initial therapy. However, a meta-analysisapproach to the use of b-blockers as the initial therapy for the
management of hypertensive patients younger than the age of
60.2 A further meta-analysis by Kuyper and Khan in this
Canadian Journal of Cardiology supplement brings more
clarity to the issue.3 In this article, we will brieﬂy review the
pharmacokinetic and pharmacodynamic properties of this
drug class (for a detailed review please see the article by Poirier
and Tobe4 in this supplement to the Canadian Journal of
Cardiology) and the major studies that are used in the meta-
analysis.
b-Blockers have different pharmacodynamic and pharma-
cokinetic properties (see Table 1). Some b-blockers can be
more selective for the b1 receptor and some can be described
to have a property of intrinsic sympathomimetic activity on
the b-receptor. They can be vasodilating with a-adrenergic
blocking properties (labetolol/carvedilol) or with an increased
production of nitric oxide (nebivolol). The metabolism can be
inﬂuenced by genetic polyphormisms as has been demon-
strated for metoprolol, nebivolol, and carvedilol.5-7 They can
have various degrees of lipophilicity, allowing entry to the
central nervous system and greater side effects. Their meta-
bolism affects the route of elimination with the lipophilic
agents metabolized by the liver and their excretion potentially
slowed by hepatic congestion with congestive heart failure.pen access under CC BY-NC-ND license.
and after myocardial infarction, and other indications such as migraine
and essential tremor. There have been more than 17 large trials
inﬂuencing the recommendations on the use of these agents in the
treatment of hypertension. The results of these trials initially led to the
widespread recommendation for the use of b-blockers in the man-
agement of hypertension. However, the recent multiple meta-analyses
using these trials have raised a controversy on their place in that
treatment. The Canadian Hypertension Education Program recom-
mendations have included b-blockers as a ﬁrst-line treatment option
for patients younger than 60 years of age based on the evidence from
these large trials, and this has been supported by 2 of the meta-
analyses. This article reviews these studies to help clinicians better
understand the role of b-blockers in managing hypertension.
queurs sont indiques contre les maladies cardiovasculaires comme
l’angine, la maîtrise de la frequence associee à la ﬁbrillation auricu-
laire, l’insufﬁsance cardiaque chronique, ainsi qu’après l’infarctus du
myocarde, et ont d’autres indications comme la migraine et le trem-
blement essentiel. Il y a eu plus de 17 essais d’envergure inﬂuençant
les recommandations d’utilisation de ces agents dans le traitement de
l’hypertension. Les resultats de ces essais menaient initialement à la
recommandation generale d’utilisation des b-bloqueurs dans la prise
en charge de l’hypertension. Cependant, les nombreuses recentes
meta-analyses utilisant ces essais ont souleve une controverse sur leur
place dans ce traitement. Selon les donnees scientiﬁques de ces
essais d’envergure, les recommandations du Programme educatif
canadien sur l’hypertension ont propose les b-bloqueurs comme option
de traitement de première intention chez les patients de moins de 60
ans, et cela a ete corrobore par 2 des meta-analyses. Cet article passe
en revue ces etudes pour aider les cliniciens à mieux comprendre le
rôle des b-bloqueurs dans la prise en charge de l’hypertension.
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b-Blockers and Clinical StudiesThe hydrophilic agents are typically excreted in the urine as
with atenolol and drug levels might increase with lower levels
of renal function. Thus, this class of drugs, although deﬁned
as b-adrenergic receptor blockers or b-blockers are in fact a
diverse group of medications with a wide range of properties
differentiating these drugs from each other in the treatment of
hypertension.
The b-blockers could therefore be subdivided according to
their cardioselectivity, their intrinsic sympathomimetic activity,
their vasodilatory properties, and their hydro- or lipophilicity.8
b-Blockers are traditionally thought of for cardiovascular
disease because they reduce myocardial oxygen consumption,
reduce heart rate, and reduce blood pressure (BP) at rest or at
exercise. As such, they are used in the long-termmanagement of
angina where they have been shown to be associated with good
outcomes although their effect on mortality is questioned.9
They can be combined with long-acting and short-acting ni-
trates and dihydropyridine calcium channel blockers. They have
been reported to signiﬁcantly reduce the rate of reinfarction and
mortality after acute MI.10,11 They are now indicated in the
treatment of chronic heart failure from left ventricular systolic
dysfunction because of their property of blockade of the
neurohormonal activity of the sympathetic system. They have
been shown to reduce mortality and produce symptomatic
improvements in these patients. b-Blockers produce their effect
through competitive inhibition on the effects of catecholamines,
which activate the adrenergic receptors.
b-Blockers are commonly used for the treatment of hyper-
tension which is still one of the major risk factors forTable 1. Pharmacokinetic and pharmacodynamic properties of commonly u
Property b1 selectivity (less/more) Degree of ISA (none/so
Hydrophilic Nonselective: nadolol, timolol, sotalol,
pindolol; selective:
atenololþ
None: atenolol, nadolol, ti
sotalol; some: labetolol
Lipophilic Nonselective: propranolol; selective:
metoprololþ, acebutolol, bisoprololþ,
nebivololþþ
None: propranolol, metopr
bisoprolol, carvedilol, ne
some: acebutololþ, pind
The þ and þþ indicate the relative degree of selectivity or degree of b1 selecti
ISA, intrinsic sympathomimetic activity.
Data from references.5-8cardiovascular and cerebrovascular disease. The most recent
data from the study of the Global Burden of Disease,12 eval-
uating the risks associated with various noncommunicable
diseases in all countries, highlights the growing burden of
disease attributable to noncommunicable disease. This World
Health Organization-sponsored study has reported that high
BP is the most common individual risk factor associated with
death and the most frequent individual risk factor associated
with the burden of disease. The following b-blocker clinical
trials have had an effect on the clinical practice guidelines for
the use of these agents in hypertension.Clinical Trials of b-Blockers in Hypertension
There are many trials that have evaluated the effects of
various b-blockers on outcomes in patients with hypertension.
One of the questions that has been raised since the use of
these antihypertensive agents is whether the beneﬁt of their
use is from their BP-lowering effect or their mechanism of
action or both. This debate is still ongoing but is similar to the
debates on the use of calcium channel blockers 15-20 years
ago,13 a-receptor blockers 10-15 years ago,14 and the ongoing
debate of the mechanism of blockade of the renin-angiotensin
system through either the angiotensin II type 1 receptor or the
inhibition of the angiotensin-converting enzyme.15,16
The major clinical studies shown in Table 2 were included
in most of the meta-analyses on the use of b-blockers. These
protocols are important in the understanding of the effect of
this class of agents in patients with hypertension. A variety ofsed b-blockers
me) Vasodilatory (yes/no)
Metabolism inﬂuenced by
genetic polymorphism (yes/no)
molol, Yes: labetolol; no: atenolol,
nadolol, timolol, sotalol
d
olol,
bivolol;
ololþþ
Yes: carvedilol, nebivolol; no:
propranolol, metoprolol,
bisoprolol, acebutolol, pindolol
Yes: metoprolol,5 nebivolol,6
carvedilol7
vity and ISA.7
Table 2. Trials with b-blockers in hypertension
Drug Year Study
Propranolol 1985 MRC, trial of mild hypertension17
Oxprenolol 1985 IPPSH18
Pindolol 1991 STOP-Hypertension19
Pindolol 1999 STOP-220
Metoprolol 1987 HAPPHY21
Metoprolol 1988 MAPHY22
Metoprolol 1991 STOP-Hypertension19
Metoprolol 1999 STOP-220
Metoprolol 1999 CAPPP23
Metoprolol 2002 AASK24
Atenolol 1986 HEP25
Atenolol 1987 HAPPHY21
Atenolol 1991 STOP-Hypertension19
Atenolol 1999 STOP-220
Atenolol 1992 MRC, treatment of hypertension in older adults26
Atenolol 1999 CAPPP23
Atenolol 1998 UKPDS27
Atenolol 2002 AASK24
Atenolol 2002 ELSA28
Atenolol 2002 LIFE29
Atenolol 2003 INVEST30
Atenolol 2003 CONVINCE31
Atenolol 2005 ASCOT-BPLA32
AASK, African American Study of Kidney Disease and Hypertension;
ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure
Lowering Arm; CAPPP, Captopril Primary Prevention Project;
CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular
End Points; ELSA, European Lacidipine Study on Atherosclerosis; HAPPHY,
Heart Attack Primary Prevention in Hypertension; HEP, Hypertension in
Elderly Patients in Primary Care; INVEST, International Verapamil-
Trandolapril Study; IPPSH, International Prospective Primary Prevention
Study in Hypertensives; LIFE, Losartan Intervention For Endpoint Reduc-
tion in Hypertension; MAPHY, Metoprolol Atherosclerosis Prevention in
Hypertensives; MRC, Medical Research Council; STOP-2, Swedish Trial in
Old Patients with Hypertension-2; STOP-Hypertension, Swedish Trial in
Old Patients with Hypertension; UKPDS, UK Prospective Diabetes Study.
Adapted from Kuyper and Khan3 with permission from Elsevier.
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Volume 30 2014b-blockers were used in these studies: propranolol was used in
1 trial, oxprenolol in 1 trial, pindolol in 2 trials, metoprolol
was used in 6 trials, and atenolol in 13 trials, and none used
vasodilating b-blockers.
The ﬁrst major trial on b-blockers was the Medical
Research Council trial in the treatment of mild hypertension
comparing a thiazide with propranolol and with placebo.17
The pilot study of this trial ran from 1973 to 1977 in the
United Kingdom with 1849 patients, and the main trial was
completed in 1985 with publication later in the year with
17,354 patients from the ages of 35 to 64 years followed for 5
years. The aim of this protocol was to determine whether drug
treatment of mild hypertension reduced the rate of stroke,
coronary events, and death. It also evaluated the cardiovas-
cular protective efﬁcacy of a thiazide or propranolol compared
with placebo. The results indicated that active treatment
reduced strokes but not coronary events. A secondary analysis
reported that thiazides reduced more strokes than b-blockers
and that b-blockers appeared to be effective only in hyper-
tensive nonsmokers. All-cause mortality was reduced in men
but not in women. One weakness of this study was the
presence of normotensive individuals in this trial. The authors
report that one-third to half of the patients taking placebo
were normotensive during the trial and had a diastolic pressure
<90 mm Hg. This very high percentage of normotensiveindiviuals could explain the low number of events and the
limited beneﬁt of treatments.
In the subsequent Medical Research Council trial in elderly
patients26 completed in 1991, 4396 patients between the ages
of 65 and 74 years were randomized single blind to receive a
hydrochlorothiazide-amiloride combination compared with
atenolol and matching placebo. The objective was to evaluate
if active treatment reduced all-cause mortality and morbidity
due to strokes and coronary events. There was a signiﬁcant
reduction in fatal and nonfatal strokes with the active treat-
ment but the reduction in fatal strokes was conﬁned to the
diuretic-treated and the reduction in nonfatal strokes was
present in both active treatment groups. Coronary events were
reduced although not signiﬁcantly and there was an overall
reduction in cardiovascular events by the active treatment
mainly attributed to the diuretic agents. All-cause mortality
was not signiﬁcantly reduced. BP was reduced to a greater
extent in the diuretic group for the ﬁrst 3 months of the trial
but became similar in the 2 groups with greater add-on sup-
plementation in the b-blocker group. Major weaknesses in
this study included 25% of the patients lost to follow-up and
more than 50% of patients were not taking any of their
randomized treatment at the end of the trial, including 63%
allocated to b-blockers.
In the Heart Attack Primary Prevention in Hypertension
(HAPPHY) trial,21 diuretics (bendroﬂuazide or hydrochloro-
thiazide) were compared with b-blockers (metoprolol or
atenolol) in an open randomized trial on coronary artery
events and deaths in 6569 patients aged from 40 to 64 years.
There were no signiﬁcant differences in the end points be-
tween the 2 groups of drugs. The trial was done only in men
and the choice of the treatments after randomization was left
open to the various centres. Therefore, the results were allo-
cated to the b-blocker group or to the thiazide group and not
a speciﬁc agent. TheMetoprolol Atherosclerosis Prevention in
Hypertensives (MAPHY) trial22 was a follow-up extension of
the HAPPHY trial, including only patients who had been
randomized to metoprolol compared with thiazide diuretics.
The follow-up median time was 4.2 years and results indicated
a lower total and cardiovascular mortality in the group taking
the b-blocker. Not all patients were included, and this was an
open follow-up of patients allocated to that group.
In the Swedish Trial in Old Patients With Hypertension
(STOP-Hypertension) trial, 1627 patients with an average age
of 75.7 years and an initial BP of 195/102 mm Hg were
randomized to active treatments or a matching placebo.19 The
active treatments were atenolol, metoprolol, pindolol, or hy-
drochlorothiazide with amiloride, and each participating
centre was allowed to use only 1 of the 4 treatments. There
was a signiﬁcant reduction in fatal and nonfatal strokes and
cardiovascular mortality but the difference could not be
evaluated between the 4 treatment groups. In the STOP-2
trial, 6614 elderly patients between the ages of 70 and 84
years with a baseline BP of 194/98 mm Hg were randomized
in a prospective open randomized trial with blinded end
points design to 3 treatment groups: conventional therapy
(b-blockers with diuretics), angiotensin-converting enzyme
inhibitors, and calcium channel blockers.20 The b-blockers
were the same as in the initial STOP study. All 3 treatments
groups showed similar efﬁcacy in prevention of cardiovascular
end points of cardiovascular mortality and major morbidity
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b-Blockers and Clinical Studiesbut the results of the effects of b-adrenergic blockers were
included in the group of conventional treatment. The results
were allocated to either b-blockers or diuretics without actual
information on either group and the choice of drugs in the
group was not randomized.
In the UK Prospective Diabetes Study (UKPDS) trial,27
there were 1148 hypertensive patients with type 2 diabetes
mellitus with a mean age of 56 years and a mean BP of 160/94
mm Hg of whom 758 were allocated to a tight control of BP
using either captopril, an angiotensin-converting enzyme in-
hibitor, or atenolol. Both treatments were equally effective in
reducing BP and also equally effective in reducing macro-
vascular end points, deaths, MI, and stroke. The sample size,
however, was small.
The largest trial that investigated b-blockers, the Interna-
tional Verapamil-Trandolapril Study (INVEST) trial,30 ran-
domized 22,576 patients with hypertension and coronary
artery disease to compare mortality and morbidity (nonfatal
MI or stroke, cardiovascular death of all-cause) outcomes in
patients treated with a calcium antagonist strategy or a non-
calcium antagonist strategy based on atenolol. To reach the
target BP of 140/90 or 130/85 for patients with diabetes,
trandolapril and/or hydrochlorothiazide were added to the
treatments. The average age was 66 years, 30% were older
than the age of 70 years, 85% were already taking antihy-
pertensive medication, and the baseline BP was 149/86 mm
Hg. The atenolol-based strategy was as effective as the calcium
channel blocker-based strategy and proved to be as effective as
the other on protection for the mentioned events including
cardiac and stroke. This study demonstrated the effectiveness
of a strategy based on b-blockers in patients with hypertension
and coronary artery disease.
The Losartan Intervention For Endpoint Reduction in Hy-
pertension (LIFE) trial29 was a double-blindmasked randomized
parallel group trial in 9193 patients with hypertension and left
ventricular hypertrophy and an average age of 66 years (range, 55-
80 years). Patients were randomized to an atenolol-based strategy
or a losartan-based strategy. Baseline BP was 174/98 and BP
decreased signiﬁcantly, 30/16mmHg in both groups. There was
a greater reduction in the number of cardiovascular end points:
MI, stroke, and death in the group taking losartan. The angio-
tensin receptor blocker-based strategy also reduced fatal and
nonfatal strokes more than the atenolol-based strategy, and
prevented new-onset atrial ﬁbrillation compared with atenolol.
The Controlled Onset Verapamil Investigation of Car-
diovascular End Points (CONVINCE) trial31 was a random-
ized double-parallel group, actively controlled multicentre
trial with a follow-up of 5 years. It compared 2 treatment
regimens in 16,602 hypertensive patients with 1 additional
risk factor on the rate of fatal and nonfatal MI, stroke, and
cardiovascular-related deaths, and also tested whether abro-
gating the early morning increase in BP with a chrono-
biologically prepared form of verapamil would be more
effective. One treatment regimen was based on a controlled-
release verapamil and the other on either hydrochlorothiazide
or atenolol. Of the 8361 patients randomized to the hydro-
chlorothiazide with atenolol group, 4482 (53.6%) were
preselected to atenolol. The results were unable to demon-
strate the equivalence of the verapamil-based antihypertensive
regimen compared with a regimen beginning with a diuretic
or a b-blocker (based on the upper bound of the 95%conﬁdence intervals for the primary end point not exceeding
1.16dit was 1.18). These data indicated that the effective-
ness of the calcium channel blocker in reducing cardiovas-
cular disease was similar but not better than a diuretic- or b-
blocker-based treatment. The CONVINCE study was
stopped early by the sponsor and the primary event number
(stroke, MI, or cardiovascular disease-related death) was 729
compared with the 2024 estimated to be needed. Although
more participants had primary events from 6 am until noon,
there was no beneﬁt observed during this time period for the
chronobiologically correct verapamil.
Finally the Anglo-Scandinavian Cardiac Outcomes Trial-
Blood Pressure Lowering Arm (ASCOT-BPLA) trial32
compared an antihypertensive regimen based on amlodipine
with perindopril as required to reach BP targets, with a
regimen based on atenolol with bendroﬂumethazide and po-
tassium as required. The protocol was stopped prematurely
although there was not a signiﬁcant difference in the com-
bined end points. There was a statistically signiﬁcant differ-
ence in fatal and nonfatal strokes, total cardiovascular events
and procedures, and all-cause mortality in favour of the
amlodipine with perindopril combination. The amlodipine
with perindopril combination prevented more events than the
atenolol with diuretic combination.
The Conduit Artery Function Evaluation (CAFE) sub-
study assessed central BP indirectly and found lower central
pressure in the amlodipine-based therapy group associated
with improved outcomes compared with the atenolol-based
therapy group. It is not known if the higher central BP
with atenolol was due to relative vasoconstriction affecting
wave reﬂection or a slower heart rate delaying the peak of
the outgoing pressure wave leading to augmentation of re-
ﬂected waves.33Meta-analyses of Studies With b-Blockers
In 1998, Messerli et al. conducted the ﬁrst meta-analysis of
studies that compared the use of b-blockers with diuretics in
patients with hypertension considered to be elderly (60 years
of age).34 Ten protocols were included with 8217 patients
taking b-blockers or diuretics and a follow-up of 5 years. In
this meta-analysis, both groups of treatments reduced cere-
brovascular events but b-blockers did not reduce coronary
artery events or mortality. The authors concluded that b-
blockers should no longer be ﬁrst-line therapy for elderly
patients.
In 2001, a meta-analysis by Staessen et al. of 9 trials
including 62,605 patients concluded that all antihypertensive
agents that included the older drugs, diuretics, b-blockers, and
newer agents including calcium channel blockers and
angiotensin-converting enzyme inhibitors had similar long-
term efﬁcacy and safety.35 The beneﬁt of the BP-lowering
accounted for most of the differences in outcomes. Howev-
er, the results of the trials and BP reductions with b-blockers
and diuretics, were analyzed together and no separate results
were reported.
In 2005, Lindholm et al. reported a meta-analysis of 13
trials that compared b-blockers with other treatments in
105,951 subjects with primary hypertension and 7 trials that
compared b-blockers with placebo or no treatment in 27,433
patients.1 In the active treatment comparator, there was an
S20 Canadian Journal of Cardiology
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antihypertensive agents. b-Blockers reduced the risk of stroke
in the placebo-controlled trials but only by half of what was
expected with other agents. In a later publication, the same
group of authors36 attributed the less positive effect of the
b-blockers on the speciﬁc use of atenolol although no trial has
compared the use of atenolol with other b-blockers.
A Cochrane review by Wiysonge et al. in 2012 of 13
protocols with 97,507 patients including 40,245 taking
b-blockers, of whom three-quarters were taking atenolol.37
The comparators were placebo, diuretics, calcium channel
blockers, and renin-angiotensin system inhibitors. They
concluded that initiating treatment with b-blockers leads to a
modest reduction in cardiovascular disease but the quality of
the evidence was judged to be low, so that the true effect of b-
blockers was possibly substantially different from the estimate
found in their review. They also pointed out that further
research should explore whether there are differences between
b-blockers, focusing on differential effects between younger
and older patients.
The most recent meta-analysis is the update in this sup-
plement of the Canadian Journal of Cardiology by Kuyper and
Khan3 of a previous meta-analysis by Khan and McAlister.2
That analysis included 145,811 participants in 21 hyperten-
sion trials and concluded that the use of b-adrenergic blockers
in hypertension is associated with a signiﬁcant reduction in
cardiovascular morbidity and mortality in younger patients
but should not be considered for ﬁrst-line therapy in older
patients. In this update, the authors sought to compare the
efﬁcacy of b-blockers stratiﬁed according to atenolol vs non-
atenolol b-blockers, and also according to age. They
concluded that atenolol and nonatenolol b-blockers decrease
cardiovascular end points in young patients, suggesting that
age might be a more important factor than the choice of
b-blocker. They also concluded that atenolol is not an
appropriate choice for uncomplicated hypertension in older
hypertensive patients with signiﬁcantly worse outcomes,
although whether this is a class effect or speciﬁc to atenolol
remains unclear. It is tempting to link the lack of efﬁcacy of
b-blockers as initial therapy in the elderly population with
hypertension to a lack of lowering of central BP as was found
in the CAFE study, but this is only a hypothesis at this time.
It is also possible that the adverse metabolic effects of the
nonvasodilating b-blockers might be a contributing factor, but
this remains to be proven in a hard outcomes study.
The Blood Pressure Lowering Treatment Trialist Collab-
oration38 used individual data for their analysis and reported
no clear differences between age groups in the effects of
lowering BP and no strong evidence that a protective effect
against major cardiovascular events could be related to the use
of a class of antihypertensive agent.
The Blood Pressure Lowering Treatment Trialist Collab-
oration evaluated 31 trials and 190,906 participants. How-
ever, b-blockers and diuretics were included together as a class
of conventional agents. They reported that further analysis
was not able to detect differences when b-blockers were
considered separately.
The largest meta-analysis was conducted by Law in 2009
in 108 trials with 464,000 patients to determine the quanti-
tative efﬁcacy of different classes of BP-lowering drugs in pre-
venting coronary artery disease and strokes.39 In their analysis,b-blockers had an improvement beyond what was expected
from BP reduction alone in preventing recurrent coronary heart
disease events in people when given shortly after a myocardial
infarction. According to their analysis, the 5 main classes of
antihypertensive drugs (thiazides, calcium channel blockers, b-
blockers, angiotensin receptor blockers, and angiotensin-
converting enzyme inhibitors) were similarly effective within
a few percentage points in preventing coronary heart disease
and stroke.Conclusions
In conclusion, b-adrenergic receptor blockers have been
used for more than 45 years in the treatment of hypertension
and in various other clinical situations. They have diverse
pharmacokinetic and pharmacodynamic properties. The
studies included in the various meta-analyses were done from
1973 to 2012 and used a variety of b-blockers in patients
young and old with mild to severe hypertension.
The recent meta-analyses which have speciﬁcally investi-
gated the effect of b-blockers in the treatment of hypertension
have conﬁrmed their efﬁcacy in the reduction of cardiovas-
cular morbidity and mortality but mainly in younger patients
and less in older patients, because there is an excess risk of
stroke in older patients with b-blockers compared with other
antihypertensive agents. The meta-analysis by Kuyper and
Khan also concludes that this class of agents decreases car-
diovascular end points in younger patients, suggesting that age
might be a more important factor than the choice of
b-blocker.3 Atenolol appears not to be an appropriate choice
for uncomplicated hypertension with worse outcomes,
although whether this a class effect or speciﬁc to atenolol re-
mains unclear.
The role of b-blockers was also reviewed recently by Poirier
and Lacourcière, who concluded that although b-blockers are
clearly effective in reducing BP, the mechanism of action of
conventional oral b-blockers, which depend on the reduction
of heart rate and cardiac output, might not be optimal because
there is lack of effect on peripheral resistance in the short-
term.40 It is tempting to link the lack of efﬁcacy of b-blockers
as initial therapy in elderly patients with hypertension to a lack
of lowering of central BP as was found in the CAFE study, but
this is only a hypothesis at this time. It is also possible that the
adverse metabolic effects of the nonvasodilating b-blockers
might be a contributing factor, but this remains to be proven
in a hard outcomes study.
There are no studies, however, that compared outcomes in
the treatment of hypertension with the various subclasses of
b-blockers or b-blockers with different properties such as the
vasodilating b-blockers.
The Canadian Hypertension Education Program guide-
lines continue to support the use of b-blockers as initial
treatment in patients younger than 60 years of age, and as part
of combination therapy, using the evidence available from
outcome trials and meta-analyses. There is a lack of data in
comparisons of outcomes of different b-blockers and in
particular, comparisons of hard cardiovascular outcomes be-
tween vasodilating and nonvasodilating b-blockers in hyper-
tension. Unfortunately, no further randomized controlled
trials with hard outcomes are planned (based on search of 443
studies on the clinicaltrials.gov Web site, in February 2014 for
Larochelle et al. S21
b-Blockers and Clinical Studieshypertension and b-blockers). This leaves clinicians who want
to take an evidence-based approach to their use of b-blockers
dependent on meta-analyses of older studies, many with
weaker methodologies or on studies with surrogate outcomes.Funding Sources
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